Drug Trial Radar · NCT06045806
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
79
Actual
Start
Oct 16, 2023
Primary completion
Aug 11, 2025
Study completion Nov 20, 2029
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb; 2seventy bio
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Conditions
- Multiple Myeloma
Interventions
idecabtagene vicleucelBiological
Specified dose on specified days
LenalidomideDrug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 50 months after the first participant is randomized
Locations
101 sites in 18 countries. Site status is shown where the registry gives one.
Local Institution - 0131
Los Angeles, California
Local Institution - 0126
Orange, California
Local Institution - 0113
Sacramento, California
Colorado Blood Cancer Institute
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
AdventHealth Orlando
Orlando, Florida
Local Institution - 0121
Atlanta, Georgia
Local Institution - 0104
Atlanta, Georgia
Local Institution - 0151
Boston, Massachusetts
Ascension Providence Hospital
Southfield, Michigan
M Health Fairview Clinics and Surgery Center
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Columbia University Irving Medical Center
New York, New York
Novant Health Cancer Institute - Elizabeth
Charlotte, North Carolina
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Local Institution - 0132
Philadelphia, Pennsylvania
Local Institution - 0124
Austin, Texas
Local Institution - 0109
Houston, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Local Institution - 0007
Camperdown, New South Wales, Australia
Local Institution - 0005
Brisbane, Queensland, Australia
Local Institution - 0004
Melbourne, Victoria, Australia
Local Institution - 0006
Melbourne, Victoria, Australia
Local Institution - 0008
Melbourne, Victoria, Australia
Local Institution - 0011
Murdoch, Western Australia, Australia
Local Institution - 0089
Salzburg, Austria
Local Institution - 0090
Vienna, Austria
Local Institution - 0083
Anderlecht, Bruxelles-Capitale, Région de, Belgium
Local Institution - 0084
Brussels, Bruxelles-Capitale, Région de, Belgium
Local Institution - 0144
Brussels, Bruxelles-Capitale, Région de, Belgium
Local Institution - 0133
Edmonton, Alberta, Canada
Local Institution - 0001
Hamilton, Ontario, Canada
Local Institution - 0134
Montreal, Quebec, Canada
Local Institution - 0070
Odense, Region Syddanmark, Denmark
Local Institution - 0082
Paris, France
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE
Toulouse, France
Local Institution - 0047
Pessac, Aquitaine, France
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France
Local Institution - 0031
Paris, Île-de-France Region, France
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.